{
    "organizations": [],
    "uuid": "ee0e0015a4f158e990713f8cd74392135fd8bbcb",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ptc-therapeutics-receives-formal-d/brief-ptc-therapeutics-receives-formal-dispute-resolution-request-decision-idUSFWN1QA0KG",
    "ord_in_thread": 0,
    "title": "BRIEF-PTC Therapeutics Receives Formal Dispute Resolution Request Decision",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - PTC Therapeutics Inc:\n* PTC THERAPEUTICS RECEIVES FORMAL DISPUTE RESOLUTION REQUEST DECISION FROM THE FDA‘S OFFICE OF NEW DRUGS\n* PTC THERAPEUTICS INC - OFFICE OF NEW DRUGS OF U.S. FDA DENIED PTC‘S APPEAL OF COMPLETE RESPONSE LETTER IN RELATION TO NDA FOR ATALUREN\n* PTC THERAPEUTICS INC - OFFICE OF NEW DRUGS RECOMMENDED A POSSIBLE PATH FORWARD FOR ATALUREN NDA SUBMISSION BASED ON ACCELERATED APPROVAL PATHWAY\n* PTC THERAPEUTICS- LETTER FROM OFFICE OF NEW DRUGS ADDS CO‘S STUDY 041 COULD SERVE AS CONFIRMATORY POST-APPROVAL TRIAL NEEDED FOR ACCELERATED APPROVAL\n* PTC THERAPEUTICS INC - PTC CURRENTLY INTENDS TO MAINTAIN PATIENTS IN U.S. CURRENTLY RECEIVING ATALUREN FOR NMDMD Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-20T21:18:00.000+02:00",
    "crawled": "2018-02-21T21:42:20.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "ptc",
        "therapeutic",
        "inc",
        "ptc",
        "therapeutic",
        "receives",
        "formal",
        "dispute",
        "resolution",
        "request",
        "decision",
        "fda",
        "office",
        "new",
        "drug",
        "ptc",
        "therapeutic",
        "inc",
        "office",
        "new",
        "drug",
        "fda",
        "denied",
        "ptc",
        "appeal",
        "complete",
        "response",
        "letter",
        "relation",
        "nda",
        "ataluren",
        "ptc",
        "therapeutic",
        "inc",
        "office",
        "new",
        "drug",
        "recommended",
        "possible",
        "path",
        "forward",
        "ataluren",
        "nda",
        "submission",
        "based",
        "accelerated",
        "approval",
        "pathway",
        "ptc",
        "letter",
        "office",
        "new",
        "drug",
        "add",
        "co",
        "study",
        "could",
        "serve",
        "confirmatory",
        "trial",
        "needed",
        "accelerated",
        "approval",
        "ptc",
        "therapeutic",
        "inc",
        "ptc",
        "currently",
        "intends",
        "maintain",
        "patient",
        "currently",
        "receiving",
        "ataluren",
        "nmdmd",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}